The Blue Valley Post talked to Dr. Chris Bowser about trends local emergency departments see over the warmer months and how to avoid becoming part of the trend.
A new study by Dr. Kosiborod and colleagues found clinical benefits in treatment with empagliflozin for patients hospitalized with acute heart failure.
A secondary analysis of the EMPULSE trial provides more context to the quality-of-life benefits of the early initiation of empagliflozin in patients hospitalized with acute decompensated heart failure.
Study shows patients with acute heart failure assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo.